Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 25, 2014

GLP-1 Receptor Agonist and Basal Insulin Combination Effective for T2DM Treatment

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Glucagon-Like Peptide-1 Receptor Agonist and Basal Insulin Combination Treatment for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis
Lancet 2014 Sep 12;[EPub Ahead of Print], C Eng, CK Kramer, B Zinman, R Retnakaran

Further Reading